Note on Reported Gilead Licenses for Hepatitis C Medicine
Gilead is reported to be in talks to issue voluntary licenses to Indian generic manufacturers for the production of sofosbuvir,…
US PhRMA Bares its Fangs – South Africa Patent Law Reform and Access to Medicine at Risk Yet Again
PhRMA (Pharmaceutical Researchers and Manufacturers of America) is putting $350,000 on the table to stop proposed patent law reform in…
Analysis of Territorial Access Issues in the MPP/BMS Atazanavir License
On December 11, the Medicines Patent Pool announced a new licensing agreement for a 2013 WHO recommended second-line antiretroviral, atazanavir…
Differential Treatment and Developing Country Transition Periods in the IP Chapter of the TPP
Inside U.S. Trade (Nov. 27, 2013) has reported that the U.S. floated a non-paper proposal for differential treatment and a…
US’s Proposed TPP Transition Period for Middle-Income Parties is Fools Gold
Inside US Trade[1] and the USTR[2] have announced that the U.S. is floating new proposals on IP in its marathon…
Investor-State Disputes Under Trade Agreements and the Affordability of Medical Care
Investor-state dispute resolution is a growing concern for governments like Canada that should want to preserve policy space for regulating…
US Pharma v. India Patent Act: Myths Abound
The U.S. pharmaceutical industry and its Big Brother Chamber of Commerce have launched an all-out disinformation campaign against the India…
Brazilian Patent Law Report
The Brazilian Center for Strategic Studies and Debates has just released the English version of its major report – Brazil’s…
Threat of Pharmaceutical-Related IP Investment Rights in the Trans-Pacific Partnership Agreement: An Eli Lilly v. Canada Case Study
After losing two patent cases before the appellate courts of a Western democracy, should a disgruntled foreign multinational pharmaceutical company…
With One Exception Current Trade Agreements Do Not Appear to Include Biologic Medicines in their Data Protection/Data Exclusivity Provisions – Implications for TPP Negotiation
The U.S., acting on behalf of the U.S. biologics industries, will soon be trying to convince parties to the TPP…
Civil Society Statement in Support of Brazilian Patent Law Reform
[UPDATE: Spanish version of the statement added July 21.] Activists and progressive health forces in Brazil have succeeded in catalyzing…
Open for Signature: Letter in Support of Proposal to Amend Brazil’s Patent Law to Take Advantage of TRIPS Flexibilities
As many of you may have heard, Brazil has been engaged in a long process of studying patent law reform…